Positive FDA review sends Optimer soaring. K-V cuts price of Makena Print E-mail
By BioMedReports.com Staff   
Friday, 01 April 2011 18:52
Below is a look at some of the headlines for companies that made news in the healthcare sector on April 01, 2011.

Shares of Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) jumped 11% Friday after a positive review from the FDA for the company's experimental antibiotic drug to prevent infection of the digestive tract. The memo stated that study data back use of its antibiotic fidaxomicin to treat infections caused by Clostridium difficile, a bacteria which causes diarrhea and inflammation of the colon. The FDA report said that patients showed significantly fewer recurrences of infection compared to those taking another antibiotic. An FDA panel will meet Tuesday April 5th to vote on the benefits and risks of fidaxomicin. The drug has a PDUFA date of May 30th.

More than 3 million shares traded hands driving the stock up $1.30 to $13.13.

K-V Pharmaceutical Company (NYSE:KVa) announced today that it will reduce the cost of Makena(hydroxyprogesterone caproate injection) by nearly 55 percent, to $690 per injection.

"Ensuring access to an FDA-approved sterile, injectable medication, manufactured under mandatory strict quality controls, is in the best interests of all high-risk women," said Greg Divis, Chief Executive Officer, K-V Pharmaceutical Company and President, Ther-Rx Corporation. "We understand the concerns that key stakeholders raised under our original pricing structure. We also recognize the current budget challenges facing state Medicaid programs and other payers. In conjunction with our substantial reduction in price, it is our sincere hope that all committed stakeholders will take appropriate action to provide timely access to this important FDA-approved medication."

Labopharm Inc. (TSX:DDS.to) (NASDAQ:DDSS) today announced that it received notice from the Listings Qualifications Department of The Nasdaq Stock Market that the closing bid price of the Corporation's Market Value of Listed Securities was below the minimum requirement of US$50,000,000 for 30 consecutive business days (ended March 28, 2011) and the Corporation was therefore not in compliance with Nasdaq listing rules.

Promius Pharma, LLC, an affiliate of Dr. Reddy's Laboratories (NYSE:RDY), and Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSX:VRX.to) today jointly announced that they have signed a collaboration agreement for Cloderm Cream. Under the agreement, Promius Pharma will make an upfront payment and pay future royalties as the consideration for the right to manufacture, distribute and market Cloderm Cream in the United States, effective immediately.

Also Friday:

AdCare Health Systems, Inc. (NYSE Amex:ADK) , a leading skilled nursing and assisted living provider, held an initial closing of $2.1 million on a private placement of subordinated convertible notes due March 2014.

Altitude Organic Corporation (PINKSHEETS: AMNG), a national, publicly-traded medical marijuana company, dropped its first advertisement in the Phoenix New Times yesterday.

AVI BioPharma, Inc. (NASDAQ: AVII) today announced that it has priced an underwritten public offering of20,000,000 shares of its common stock at a price to the public of $1.50 per share for gross proceeds of $30.0 million.

Connectyx Technologies Holdings Group, Inc. (PINKSHEETS:CTYX)
manufacturer and distributor of the MedFlash®, the nation's premier Personal Health and Wellness Management System (ePHM) for maintaining personal health records (PHR), conducted a study of a random sampling of MedFlash subscribers that indicates that the largest age group is 50 years old and older.

IDenta Corp. (PINKSHEETS: IDTA) CEO Yakcov Shoham today announced that the company has released an updated form 15(c)-211.

Medical Marijuana, Inc. (PINKSHEETS:MJNA) is proud to announce that it has been assigned a second asset and management contract from CannaBANK.

University General Health System, Inc. (PINKSHEETS: UGHS) today announced that it completed the previously announced acquisition of University General Hospital, LP, and its general partner, University Hospital Systems, LLP, effective March 28, 2011.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus